Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pearce IP’s Annual Australian Patent Case Review 2025 – Now Available

Pearce IP’s Annual Australian Patent Case Review 2025 – Now Available

by | May 20, 2026

Pearce IP is pleased to release the Annual Australian Patent Case Review 2025, a comprehensive, expert analysis of all key patent decisions shaping the Australian legal landscape over the past year. Spanning 130 pages, this essential resource provides a complete overview of: All decisions delivered by the Federal Court of Australia, All decisions delivered by the Full Court on appeal & Significant decisions from the Australian Patent Office

read more
HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions

HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions

by | Feb 27, 2026

HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions. Recent developments in Australian law and practice concerning Patent Term Extensions (PTEs) and preliminary injunctions (PIs) will shake up the pharmaceutical market. For originators, generics and biosimilar sponsors alike…

read more

Recent BioBlast® Updates

New Indication Alert: Genentech’s Tecentriq® (Atezolizumab) FDA-Approved for Bladder Cancer

May 15, 2026

On 15 May 2026, Roche subsidiary Genentech announced that the FDA has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumour DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by a specified MRD assay.

Alteogen’s Biosimilar Aflibercept Approved in Korea

May 15, 2026

On 15 May 2026, Alteogen announced that the Korean Ministry of Food and Drug Safety (MFDS) has granted marketing authorisation for Eyzanfy™/ALT-L9 (aflibercept, 2mg), biosimilar to Regeneron/Bayer’s Eylea®, for all approved reference indications.

BMS and Hengrui Pharma Enter US$15.2B Strategic Collaboration

May 12, 2026

On 12 May 2026, Bristol Myers Squibb (BMS) and Hengrui Pharma announced that they have entered into global strategic collaboration and licence agreements to advance 13 early stage innovative medicines across oncology, haematology and immunology.

Celltrion Acquires France-Based Gifrer, Expects KRW 250B Revenue Uplift

May 12, 2026

On 12 May 2026, Celltrion announced that it has acquired a 100% stake in France-based healthcare firm, Gifrer.  Gifrer operates more than 9,000 pharmacy sales channels and supply networks covering about 800 hospitals across France and will continue to operate independently post-acquisition. 

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here